Adjuvant chemo- and hormonal therapy in locally advanced breast cancer: a randomized clinical study
Journal Article
·
· Int. J. Radiat. Oncol., Biol. Phys.; (United States)
Between 1977 and 1980, 118 breast cancer patients with locally advanced disease, T3B-4, any N, M0 or T1-3, tumor positive axillary apex biopsy, were randomized to one of three arms: I: radiotherapy (RT) to the breast and adjacent lymph node areas; II: RT followed by 12 cycles of cyclophosphamide, methotrexate, 5 fluorouracil (CMF) and tamoxifen during the chemotherapy period; III: 2 cycles of adriamycin and vincristine (AV), alternated with 2 cycles of CMF, then RT, followed by another 4 cycles of AV, alternated with 4 CMF; tamoxifen during the entire treatment period. The median follow-up period was 5 1/2 years. The adjuvant chemo- and hormonal therapy did not improve the overall survival; the 5-year survival was 37% for all three treatment arms. There was no statistically significant difference in RFS between the three modalities, nor when arm I was compared to arm II and III together. LR was not statistically different over the three treatment arms. In 18 of the 24 patients with LR, distant metastases appeared within a few months from the local recurrence. The menopausal status did not influence the treatment results. Dose reduction in more than 4 cycles of chemotherapy was accompanied by better results. In conclusion: adjuvant chemo- and hormonal therapy did not improve RFS and overall survival. These findings do not support the routine use of adjuvant chemo- and endocrine therapy for inoperable breast cancer.
- Research Organization:
- Netherlands Cancer Institute, Amsterdam
- OSTI ID:
- 6041661
- Journal Information:
- Int. J. Radiat. Oncol., Biol. Phys.; (United States), Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Vol. 10; ISSN IOBPD
- Country of Publication:
- United States
- Language:
- English
Similar Records
A phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer
Randomized Trial of Postoperative Adjuvant Therapy in Stage II and III Rectal Cancer to Define the Optimal Sequence of Chemotherapy and Radiotherapy: 10-Year Follow-Up
Management of non-resectable (Stage III) breast cancer
Journal Article
·
Sat Dec 31 23:00:00 EST 2005
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:20788280
Randomized Trial of Postoperative Adjuvant Therapy in Stage II and III Rectal Cancer to Define the Optimal Sequence of Chemotherapy and Radiotherapy: 10-Year Follow-Up
Journal Article
·
Mon Nov 14 23:00:00 EST 2011
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:22054401
Management of non-resectable (Stage III) breast cancer
Conference
·
Sat Sep 01 00:00:00 EDT 1979
· Int. J. Radiat. Oncol., Biol. Phys.; (United States)
·
OSTI ID:5333033
Related Subjects
550603* -- Medicine-- External Radiation in Therapy-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
ALKALOIDS
ALKYLATING AGENTS
ANTI-INFECTIVE AGENTS
ANTIBIOTICS
ANTIMETABOLITES
ANTIMITOTIC DRUGS
ANTINEOPLASTIC DRUGS
AZINES
BODY
CHEMOTHERAPY
DOXORUBICIN
DRUGS
ENDOXAN
EVALUATION
FLUOROURACILS
GLANDS
HETEROCYCLIC COMPOUNDS
HYDROXY COMPOUNDS
IMMUNOSUPPRESSIVE DRUGS
LYMPH NODES
LYMPHATIC SYSTEM
MAMMARY GLANDS
MEDICINE
MENOPAUSE
METHOTREXATE
NUCLEAR MEDICINE
ONCOVIN
ORGANIC COMPOUNDS
ORGANIC FLUORINE COMPOUNDS
ORGANIC HALOGEN COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
ORGANS
PATIENTS
PYRIMIDINES
RADIOLOGY
RADIOTHERAPY
THERAPY
URACILS
62 RADIOLOGY AND NUCLEAR MEDICINE
ALKALOIDS
ALKYLATING AGENTS
ANTI-INFECTIVE AGENTS
ANTIBIOTICS
ANTIMETABOLITES
ANTIMITOTIC DRUGS
ANTINEOPLASTIC DRUGS
AZINES
BODY
CHEMOTHERAPY
DOXORUBICIN
DRUGS
ENDOXAN
EVALUATION
FLUOROURACILS
GLANDS
HETEROCYCLIC COMPOUNDS
HYDROXY COMPOUNDS
IMMUNOSUPPRESSIVE DRUGS
LYMPH NODES
LYMPHATIC SYSTEM
MAMMARY GLANDS
MEDICINE
MENOPAUSE
METHOTREXATE
NUCLEAR MEDICINE
ONCOVIN
ORGANIC COMPOUNDS
ORGANIC FLUORINE COMPOUNDS
ORGANIC HALOGEN COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
ORGANS
PATIENTS
PYRIMIDINES
RADIOLOGY
RADIOTHERAPY
THERAPY
URACILS